Combination of transarterial chemoembolisation (TACE) plus antivirals for the management of hepatitis B-related hepatocellular carcinoma: A systematic review of the literature

Fouad, Mona; Abdel‐Rahman, Omar

doi:10.1016/j.ajg.2015.03.003

Cited by 4 publications

(1 citation statement)

References 23 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All the patients with HBsAg or HCV-RNA positivity received antiviral treatment, because studies suggest that antivirals are beneficial to the management of hepatitis-B-related HCC and sustained virological response after oral direct-acting antivirals therapy may result in improved liver dysfunction and facilitate additional HCC-directed therapy. 27 , 28 The multivariate along with univariate analyses results exhibited that baseline SII and ALBI were independent influencing factors for the OS of patients with HCC who underwent TACE.…”

Section: Discussionmentioning

confidence: 92%

Value of Preoperative Systemic Immune-Inflammation Index and Albumin-Bilirubin Grade in Patients with Hepatocellular Carcinoma Undergoing Transarterial Embolization

Ha¹,

Wang²,

Han³

et al. 2023

Turk J Gastroenterol

View full text Add to dashboard Cite

Background : The systemic immune-inflammation index reflects the systematic inflammatory status, and the albumin-bilirubin grade reflects the liver function. In patients with hepatocellular carcinoma receiving transarterial chemoembolization, their combined clinical utility has not been fully explored. Herein, we purposed to determine the prognostic worthiness of systemic immune-inflammation index–albumin-bilirubin scores in patients receiving transarterial chemoembolization for unresectable hepatocellular carcinoma. Methods: Patients who were treated with transarterial chemoembolization after being diagnosed with hepatocellular carcinoma between 2008 and 2016 were recruited for this research work. Systemic immune-inflammation index and albumin-bilirubin scores were determined prior to treatment. The clinico-pathological factors related to overall survival were determined via univariate along with multivariate analyses. Results: A total of 295 patients were retrospectively studied. Patients with systemic immune-inflammation index–albumin-bilirubin score of 2 had the worst outcomes, exhibiting a median overall survival of 11 months (95% CI, 8.44-13.56 months) in contrast with subjects in the systemic immune-inflammation index–albumin-bilirubin 1 group (median OS, 26 months; 95% CI, 21.25-30.75 months) and the systemic immune-inflammation index–albumin-bilirubin 0 class (median OS, 31 months; 95% CI, 12.76-49.24 months). The 1-, 3-, and 5-year rates of survival were 45.3%, 1.3%, and 0% for patients in the systemic immune-inflammation index–albumin-bilirubin 2 category; 76.4%, 35.0%, and 14.6% for those in the systemic immune-inflammation index–albumin-bilirubin 1 category; and 85.6%, 46.7%, and 35.0% for those in the systemic immune-inflammation index–albumin-bilirubin 0 category, respectively ( P < . 001). Conclusions: The systemic immune-inflammation index–albumin-bilirubin score could be a simple indicator to estimate the prognosis in individuals with hepatocellular carcinoma being treated with transarterial chemoembolization. Patients in the systemic immune-inflammation index–albumin-bilirubin 2 category were more likely to be related to a shorter overall survival.

show abstract

Section: Discussionmentioning

confidence: 92%